Home > Protocol Summaries: Compounds > GSK2586184 Protocol Summaries: GSK2586184 GSKStudy ID Phase Title Status 115919 phase 2 An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus Not yet recruiting 116439 phase 1 A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2586184 following a single doseof 800mg and repeat oral tablet doses of 800mg b.d and the effect of food and gender on the pharmacokinetics of oralGSK2586184 in healthy subjects Completed 116679 phase 2 A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis Recruiting
